(NP (NP-COOD (NP (NNPS Mineralocorticoids)) (CC and) (NP (NN mineralocorticoid) (NNS receptors))) (PP (IN in) (NP (NP (JJ mononuclear) (NNS leukocytes)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ pregnancy-induced) (NN hypertension))))))) (. .))
(S (S-PRP (NP-SBJ (-NONE- *-48)) (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNS mineralocorticoids))) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NP (JJ pregnancy-induced) (NN hypertension)) (PRN (-LRB- -LRB-) (NP (NN PIH)) (-RRB- -RRB-)))))))))) (, ,) (NP-SBJ-48 (PRP we)) (VP (VBD studied) (NP (NP (NP-COOD (NP (NN plasma) (NN aldosterone)) (CC and) (NP (NN 18-hydroxycorticosterone))) (NNS levels)) (PP (IN in) (NP-COOD (NP (NP (CD 25) (NNS women)) (PP (IN with) (NP (NN PIH)))) (CC and) (NP (NP (CD 25) (JJ normal) (JJ pregnant) (NNS women)) (, ,) (PP (IN as) (NP (NNS controls)))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (PRP we)) (VP (VBD evaluated) (NP (NP (NP (DT the) (NP (NP (NN mineralocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN MR)) (-RRB- -RRB-))) (NN status)) (PP (IN in) (NP (JJ mononuclear) (NNS leukocytes)))) (PP (IN in) (NP (DT the) (CD 2) (NNS groups))))) (. .))
(S (NP-SBJ-49 (NN MR) (NN count)) (VP (VBD was) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR less) (IN than) (CD 0.0005)))) (-RRB- -RRB-)) (VP (VBN decreased) (NP (-NONE- *-49)) (PP (IN in) (NP (NP (DT the) (NN PIH) (NN group)) (PRN (-LRB- -LRB-) (FRAG (NP (QP (CD 148) (CC (- +)) (CD 9)) (VBG binding) (NNS (cell sites)))) (-RRB- -RRB-)))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (NN control) (NN group)) (PRN (-LRB- -LRB-) (FRAG (NP (NP (QP (CD 300) (CC (- +)) (CD 17)) (VBG binding) (NNS (cell sites))) (: ;) (NP (NN mean) (CC (- +)) (NN SEM)))) (-RRB- -RRB-))))))) (. .))
(S (S (NP-SBJ (NP (NN Plasma) (NN aldosterone)) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NN PIH)))))) (VP (VBD was) (NP-PRD (QP (CD 281) (CC (- +)) (CD 61)) (NN (L pmol)))) (: ;)) (S (PP (IN in) (NP (JJ normal) (JJ pregnant) (NNS women))) (NP-SBJ (PRP it)) (VP (VBD was) (NP-PRD (QP (CD 697) (CC (- +)) (CD 172)) (NN (L pmol))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR less) (IN than) (CD 0.025)))) (-RRB- -RRB-))) (. .)))
(S (NP-SBJ (NN Plasma) (NN 18-hydroxycorticosterone)) (VP (VBD was) (ADVP (RB also)) (ADJP-PRD (ADJP (RB significantly) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR less) (IN than) (CD 0.025)))) (-RRB- -RRB-)) (JJR lower)) (PRN (-LRB- -LRB-) (FRAG-COOD (FRAG (NP (NN PIH)) (, ,) (NP (QP (CD 1071) (CC (- +)) (CD 149)) (NN (L pmol)))) (: ;) (FRAG (NP (NNS controls)) (, ,) (NP (QP (CD 1907) (CC (- +)) (CD 318)) (NN (L pmol))))) (-RRB- -RRB-)))) (. .))
(S (NP-SBJ-50 (DT These) (NNS values)) (VP (VBD were) (VP (VBN determined) (NP (-NONE- *-50)) (PP-TMP (IN at) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (JJ clinical) (NNS symptoms)) (PP (IN of) (NP (NN PIH))))))))) (. .))
(S (S (NP-SBJ-51 (DT These) (NNS results)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN explained) (NP (-NONE- *-51)) (PP (IN by) (NP-LGS (NP (NN receptor) (NN down-regulation)) (PP (JJ due) (TO to) (NP (NP (JJR higher) (NNS levels)) (PP (IN of) (NP (NP (NNS mineralocorticoids)) (PP (IN in) (NP (NN PIH)))))))))))) (: ;)) (S (NP-SBJ (DT a) (ADJP (RB hitherto) (JJ unknown)) (NN mineralocorticoid)) (VP (MD may) (, ,) (ADVP (RB thus)) (, ,) (VP (VB be) (ADJP-PRD (JJ responsible) (PP (IN for) (NP (DT the) (NP-COOD (NP (NN hypertension)) (CC and) (NP (JJ altered) (NN MR))) (NN status)))))) (. .)))
